Thrombin-Activatable Fibrinolysis Inhibitor; Human

General description

Native thrombin-activatable fibrinolysis inhibitor from human liver. Single chain glycoprotein synthesized in the liver. ctivated by the thrombin/thrombomodulin complex by proteolytic cleavage at Arg⁹². Circulates in plasma as a zymogen at a concentration of about 50 nM. Believed to play an important role in the interaction between procoagulant, anticoagulant, and fibrinolytic systems.

Native thrombin-activatable fibrinolysis inhibitor from human liver. Single chain glycoprotein synthesized in the liver. Circulates in plasma as a zymogen at a concentration of 50 nM. Activated by thrombin-thrombomodulin complex by proteolytic cleavage at Arg⁹². Believed to play an important role in interaction between the procoagulant, anticoagulant, and fibrinolytic systems.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Boffa, M.B., et al. 1999. Biochemistry 38, 6547.Boffa, M.B., et al. 1998. J. Biol. Chem. 273, 2127.Bajzar, L., et al. 1995. J. Biol. Chem. 270, 14477.

Packaging

50 µg in Plastic ampoule

Please refer to vial label for lot-specific concentration.

Physical form

In 150 mM NaCl, 20 mM HEPES, pH 7.4.

Preparation Note

Prepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.

Reconstitution

Following initial thaw, aliquot and freeze (-70°C).

Unit Definition

One unit is defined as the amount of enzyme that will hydrolyze 1 µM Hip-L-Arg per min at 25°C, pH 7.65.

Warning

Toxicity: Standard Handling (A)